Larson Financial Group’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$27.3K Buy
717
+176
+33% +$7.42K ﹤0.01% 1911
2026
Q2
$25.4K Buy
541
+6
+1% +$148 ﹤0.01% 1870
2026
Q1
$10.1K Hold
535
– – ﹤0.01% 2248
2025
Q4
$7.16K Buy
+535
New +$6.62K ﹤0.01% 2302
2025
Q3
– Sell
-2,932
Closed -$19K – 3573
2025
Q2
$19K Hold
2,932
– – ﹤0.01% 1512
2025
Q1
$17.2K Buy
+2,932
New +$21K ﹤0.01% 1424
2022
Q2
– Sell
-14
Closed – – 1259
2022
Q1
$0 Hold
14
– – ﹤0.01% 1125
2021
Q4
$0 Hold
14
– – ﹤0.01% 1140
2021
Q3
$1K Hold
14
– – ﹤0.01% 839
2021
Q2
$1K Buy
+14
New +$735 ﹤0.01% 780

Other funds holding DFTX

Larson Financial Group's DFTX Position: Q3 2026 in Review

Larson Financial Group increased its Definium Therapeutics (DFTX) stake by 33% in Q3 2026, buying an estimated $7.42K and bringing the position to 717 shares worth $27.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1911.

Larson Financial Group first reported a position in DFTX in Q2 2021 and has held it in 10 quarters since. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Larson Financial Group held 717 shares of Definium Therapeutics worth $27.3K as of Q3 2026.
  • Larson Financial Group bought 176 Definium Therapeutics shares in Q3 2026, an estimated $7.42K.
  • Definium Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #1911 holding.
  • Larson Financial Group first reported a position in Definium Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.